Russell Investments Group Ltd. Takes $837,000 Position in Inhibrx, Inc. (NASDAQ:INBX)

Russell Investments Group Ltd. bought a new position in shares of Inhibrx, Inc. (NASDAQ:INBX) during the 4th quarter, Holdings Channel.com reports. The firm bought 54,345 shares of the company’s stock, valued at approximately $837,000.

Other hedge funds have also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. purchased a new position in shares of Inhibrx during the 4th quarter worth about $28,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Inhibrx in the 4th quarter valued at $47,000. New York State Common Retirement Fund purchased a new stake in shares of Inhibrx during the 4th quarter valued at $53,000. Corebridge Financial Inc. acquired a new stake in shares of Inhibrx during the 4th quarter worth $89,000. Finally, Wells Fargo & Company MN purchased a new position in shares of Inhibrx in the 4th quarter worth $102,000. 82.46% of the stock is owned by institutional investors and hedge funds.

Inhibrx Stock Performance

NASDAQ INBX opened at $11.38 on Tuesday. Inhibrx, Inc. has a one year low of $10.80 and a one year high of $34.75. The company’s 50 day moving average price is $13.10 and its 200 day moving average price is $14.15.

Inhibrx (NASDAQ:INBX) last posted its earnings results on Monday, March 17th. The company reported ($3.09) earnings per share for the quarter, missing the consensus estimate of ($2.88) by ($0.21). The company had revenue of $0.10 million for the quarter. Equities analysts anticipate that Inhibrx, Inc. will post 104.88 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, JMP Securities restated a “market perform” rating on shares of Inhibrx in a research note on Wednesday, January 22nd.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.